⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGTX News
Cognition Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
CGTX
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
globenewswire.com
CGTX
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
globenewswire.com
CGTX
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
globenewswire.com
CGTX
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
globenewswire.com
CGTX
Form 8-K
sec.gov
CGTX
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
globenewswire.com
CGTX
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
globenewswire.com
CGTX
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
globenewswire.com
CGTX
Form 8-K
sec.gov
CGTX